Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited announced the cessation of 8,311 performance rights due to the lapse of conditional rights that were not satisfied. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s performance and strategic goals.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company that focuses on the development and manufacturing of branded and generic pharmaceutical products. It operates in the healthcare industry, offering a range of oral and injectable products to various markets.
Average Trading Volume: 281,912
Technical Sentiment Signal: Buy
Current Market Cap: A$459.9M
Learn more about MYX stock on TipRanks’ Stock Analysis page.